Debunking Regulatory Myths In CGT Orphan Drug Development

By Steve Winitsky, M.D., Senior Vice President, Technical, Regulatory Consulting

Cell and gene therapies (CGTs) are transforming treatment options for rare diseases, yet regulatory misconceptions continue to slow orphan drug development. Sponsors often assume that expedited designations, smaller patient populations, or novel modalities lower the evidentiary bar for approval—but these assumptions can lead to costly missteps.

This article dispels five common regulatory myths surrounding CGT orphan drug development, drawing on real‑world regulatory experience. It clarifies how FDA expedited programs truly work and what they do not change, why rigorous evidence is still essential, and when single‑arm trials, external controls, or natural history studies may be required. The article also addresses long‑term safety expectations and the importance of generating data that not only meets regulatory requirements but also differentiates a therapy in an increasingly competitive rare disease landscape.

By replacing assumptions with regulatory insight, sponsors can design more credible development strategies, align earlier with regulators, avoid common development missteps, and ultimately accelerate access to life‑changing CGT therapies for patients with rare diseases.